DELZICOL Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Delzicol, and when can generic versions of Delzicol launch?

Delzicol is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in DELZICOL is mesalamine. There are twenty-eight drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Delzicol

A generic version of DELZICOL was approved as mesalamine by PADAGIS ISRAEL on September 17^th, 2004.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for DELZICOL?
What are the global sales for DELZICOL?
What is Average Wholesale Price for DELZICOL?

Summary for DELZICOL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	181
Clinical Trials:	2
Patent Applications:	4,392
Drug Prices:	Drug price information for DELZICOL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DELZICOL
What excipients (inactive ingredients) are in DELZICOL?	DELZICOL excipients list
DailyMed Link:	DELZICOL at DailyMed

Drug patent expirations by year for DELZICOL

Recent Clinical Trials for DELZICOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AbbVie	Phase 3
Holy Stone Healthcare Co., Ltd	Phase 1

See all DELZICOL clinical trials

Pharmacology for DELZICOL

Drug Class	Aminosalicylate

Paragraph IV (Patent) Challenges for DELZICOL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DELZICOL	Delayed-release Capsules	mesalamine	400 mg	204412	1	2014-06-17

US Patents and Regulatory Information for DELZICOL

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	DELZICOL	mesalamine	CAPSULE, DELAYED RELEASE;ORAL	204412-001	Feb 1, 2013	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for DELZICOL

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	DELZICOL	mesalamine	CAPSULE, DELAYED RELEASE;ORAL	204412-001	Feb 1, 2013	⤷ Sign Up	⤷ Sign Up
Abbvie	DELZICOL	mesalamine	CAPSULE, DELAYED RELEASE;ORAL	204412-001	Feb 1, 2013	⤷ Sign Up	⤷ Sign Up
Abbvie	DELZICOL	mesalamine	CAPSULE, DELAYED RELEASE;ORAL	204412-001	Feb 1, 2013	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for DELZICOL

See the table below for patents covering DELZICOL around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Japan	2000297102	CELLULOSE ETHER FILM	⤷ Sign Up
Norway	830948		⤷ Sign Up
Finland	85216		⤷ Sign Up
European Patent Office	1045000	Films d'éther de cellulose (Cellulose ether films)	⤷ Sign Up
South Korea	20010014728		⤷ Sign Up
United Kingdom	8322387		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration